Search

Ordinal response is commonly found in medicine, biology, and other fields. In many situations, the predictors for this ordinal response are compositional, which means that the sum of predictors for each sample is fixed. Examples of compositional data include the relative abundance of species in microbiome data and the relative frequency of nutrition concentrations. Moreover, the predictors that are strongly correlated tend to have similar influence on the response outcome. Conventional cumulative logistic regression models for ordinal responses ignore the fixed-sum constraint on predictors and their associated interrelationships, and thus are not appropriate for analyzing compositional predictors. To solve this problem, we proposed Bayesian Compositional Models for Ordinal Response to analyze the relationship between compositional data and an ordinal response with a structured regularized horseshoe prior for the compositional coefficients and a soft sum-to-zero restriction on coefficients through the prior distribution. The method was implemented with R package rstan using efficient Hamiltonian Monte Carlo algorithm. We performed simulations to compare the proposed approach and existing methods for ordinal responses. Results revealed that our proposed method outperformed the existing methods in terms of parameter estimation and prediction. We also applied the proposed method to a microbiome study HMP2Data, to find microorganisms linked to ordinal inflammatory bowel disease levels. To make this work reproducible, the code and data used in this paper are available at https://github.com/Li-Zhang28/BCO. [ABSTRACT FROM AUTHOR]

This paper aims to extend the Besag model, a widely used Bayesian spatial model in disease mapping, to a non-stationary spatial model for irregular lattice-type data. The goal is to improve the model's ability to capture complex spatial dependence patterns and increase interpretability. The proposed model uses multiple precision parameters, accounting for different intensities of spatial dependence in different sub-regions. We derive a joint penalized complexity prior to the flexible local precision parameters to prevent overfitting and ensure contraction to the stationary model at a user-defined rate. The proposed methodology can be used as a basis for the development of various other non-stationary effects over other domains such as time. An accompanying R package fbesag equips the reader with the necessary tools for immediate use and application. We illustrate the novelty of the proposal by modeling the risk of dengue in Brazil, where the stationary spatial assumption fails and interesting risk profiles are estimated when accounting for spatial non-stationary. Additionally, we model different causes of death in Brazil, where we use the new model to investigate the spatial stationarity of these causes. [ABSTRACT FROM AUTHOR]

In psychophysics and psychometrics, an integral method to the discipline involves charting how a person's response pattern changes according to a continuum of stimuli. For instance, in hearing science, Visual Analog Scaling tasks are experiments in which listeners hear sounds across a speech continuum and give a numeric rating between 0 and 100 conveying whether the sound they heard was more like word "a" or more like word "b" (i.e. each participant is giving a continuous categorization response). By taking all the continuous categorization responses across the speech continuum, a parametric curve model can be fit to the data and used to analyze any individual's response pattern by speech continuum. Standard statistical modeling techniques are not able to accommodate all of the specific requirements needed to analyze these data. Thus, Bayesian hierarchical modeling techniques are employed to accommodate group-level non-linear curves, individual-specific non-linear curves, continuum-level random effects, and a subject-specific variance that is predicted by other model parameters. In this paper, a Bayesian hierarchical model is constructed to model the data from a Visual Analog Scaling task study of mono-lingual and bi-lingual participants. Any nonlinear curve function could be used and we demonstrate the technique using the 4-parameter logistic function. Overall, the model was found to fit particularly well to the data from the study and results suggested that the magnitude of the slope was what most defined the differences in response patterns between continua. [ABSTRACT FROM AUTHOR]

The Fellegi-Sunter model is a latent class model widely used in probabilistic linkage to identify records that belong to the same entity. Record linkage practitioners typically employ all available matching fields in the model with the premise that more fields convey greater information about the true match status and hence result in improved match performance. In the context of model-based clustering, it is well known that such a premise is incorrect and the inclusion of noisy variables could compromise the clustering. Variable selection procedures have therefore been developed to remove noisy variables. Although these procedures have the potential to improve record matching, they cannot be applied directly due to the ubiquity of the missing data in record linkage applications. In this paper, we modify the stepwise variable selection procedure proposed by Fop, Smart, and Murphy and extend it to account for missing data common in record linkage. Through simulation studies, our proposed method is shown to select the correct set of matching fields across various settings, leading to better-performing algorithms. The improved match performance is also seen in a real-world application. We therefore recommend the use of our proposed selection procedure to identify informative matching fields for probabilistic record linkage algorithms. [ABSTRACT FROM AUTHOR]

The focus of precision medicine is on decision support, often in the form of dynamic treatment regimes, which are sequences of decision rules. At each decision point, the decision rules determine the next treatment according to the patient's baseline characteristics, the information on treatments and responses accrued by that point, and the patient's current health status, including symptom severity and other measures. However, dynamic treatment regime estimation with ordinal outcomes is rarely studied, and rarer still in the context of interference – where one patient's treatment may affect another's outcome. In this paper, we introduce the weighted proportional odds model: a regression based, approximate doubly-robust approach to single-stage dynamic treatment regime estimation for ordinal outcomes. This method also accounts for the possibility of interference between individuals sharing a household through the use of covariate balancing weights derived from joint propensity scores. Examining different types of balancing weights, we verify the approximate double robustness of weighted proportional odds model with our adjusted weights via simulation studies. We further extend weighted proportional odds model to multi-stage dynamic treatment regime estimation with household interference, namely dynamic weighted proportional odds model. Lastly, we demonstrate our proposed methodology in the analysis of longitudinal survey data from the Population Assessment of Tobacco and Health study, which motivates this work. Furthermore, considering interference, we provide optimal treatment strategies for households to achieve smoking cessation of the pair in the household. [ABSTRACT FROM AUTHOR]

Many non-fatal events can be considered recurrent in that they can occur repeatedly over time, and some researchers may be interested in the trajectory and relative risk of non-fatal events. With the competing risk of death, the treatment effect on the mean number of recurrent events is non-identifiable since the observed mean is a function of both the recurrent event and terminal event processes. In this paper, we assume independence between the non-fatal and the terminal event process, conditional on the shared frailty, to fit a parametric model that recovers the trajectory of, and identifies the effect of treatment on, the non-fatal event process in the presence of the competing risk of death. Simulation studies are conducted to verify the reliability of our estimators. We illustrate the method and perform model diagnostics using the Carvedilol Prospective Randomized Cumulative Survival trial which involves heart-failure events. [ABSTRACT FROM AUTHOR]

One of the primary objectives of a dose-finding trial for novel anti-cancer agent combination therapies, such as molecular targeted agents and immune-oncology therapies, is to identify optimal dose combinations that are tolerable and therapeutically beneficial for subjects in subsequent clinical trials. The goal differs from that of a dose-finding trial for traditional cytotoxic agents, in which the goal is to determine the maximum tolerated dose combinations. This paper proposes the new design, named 'BOIN-ETC' design, to identify optimal dose combinations based on both efficacy and toxicity outcomes using the waterfall approach. The BOIN-ETC design is model-assisted, so it is expected to be robust, and straightforward to implement in actual oncology dose-finding trials. These characteristics are quite valuable from a practical perspective. Simulation studies show that the BOIN-ETC design has advantages compared with the other approaches in the percentage of correct optimal dose combination selection and the average number of patients allocated to the optimal dose combinations across various realistic settings. [ABSTRACT FROM AUTHOR]

Estimating treatment (or policy or intervention) effects on a single individual or unit has become increasingly important in health and biomedical sciences. One method to estimate these effects is the synthetic control method, which constructs a synthetic control, a weighted average of control units that best matches the treated unit's pre-treatment outcomes and other relevant covariates. The intervention's impact is then estimated by comparing the post-intervention outcomes of the treated unit and its synthetic control, which serves as a proxy for the counterfactual outcome had the treated unit not experienced the intervention. The augmented synthetic control method, a recent adaptation of the synthetic control method, relaxes some of the synthetic control method's assumptions for broader applicability. While synthetic controls have been used in a variety of fields, their use in public health and biomedical research is more recent, and newer methods such as the augmented synthetic control method are underutilized. This paper briefly describes the synthetic control method and its application, explains the augmented synthetic control method and its differences from the synthetic control method, and estimates the effects of an antimalarial initiative in Mozambique using both the synthetic control method and the augmented synthetic control method to highlight the advantages of using the augmented synthetic control method to analyze the impact of interventions implemented in a single region. [ABSTRACT FROM AUTHOR]

The estimation of heterogeneous treatment effects has attracted considerable interest in many disciplines, most prominently in medicine and economics. Contemporary research has so far primarily focused on continuous and binary responses where heterogeneous treatment effects are traditionally estimated by a linear model, which allows the estimation of constant or heterogeneous effects even under certain model misspecifications. More complex models for survival, count, or ordinal outcomes require stricter assumptions to reliably estimate the treatment effect. Most importantly, the noncollapsibility issue necessitates the joint estimation of treatment and prognostic effects. Model-based forests allow simultaneous estimation of covariate-dependent treatment and prognostic effects, but only for randomized trials. In this paper, we propose modifications to model-based forests to address the confounding issue in observational data. In particular, we evaluate an orthogonalization strategy originally proposed by Robinson (1988, Econometrica) in the context of model-based forests targeting heterogeneous treatment effect estimation in generalized linear models and transformation models. We found that this strategy reduces confounding effects in a simulated study with various outcome distributions. We demonstrate the practical aspects of heterogeneous treatment effect estimation for survival and ordinal outcomes by an assessment of the potentially heterogeneous effect of Riluzole on the progress of Amyotrophic Lateral Sclerosis. [ABSTRACT FROM AUTHOR]

Identifying and distinguishing risk factors for heterogeneous disease subtypes has been of great interest. However, missingness in disease subtypes is a common problem in those data analyses. Several methods have been proposed to deal with the missing data, including complete-case analysis, inverse-probability weighting, and multiple imputation. Although extant literature has compared these methods in missing problems, none has focused on the competing risk setting. In this paper, we discuss the assumptions required when complete-case analysis, inverse-probability weighting, and multiple imputation are used to deal with the missing failure subtype problem, focusing on how to implement these methods under various realistic scenarios in competing risk settings. Besides, we compare these three methods regarding their biases, efficiency, and robustness to model misspecifications using simulation studies. Our results show that complete-case analysis can be seriously biased when the missing completely at random assumption does not hold. Inverse-probability weighting and multiple imputation estimators are valid when we correctly specify the corresponding models for missingness and for imputation, and multiple imputation typically shows higher efficiency than inverse-probability weighting. However, in real-world studies, building imputation models for the missing subtypes can be more challenging than building missingness models. In that case, inverse-probability weighting could be preferred for its easy usage. We also propose two automated model selection procedures and demonstrate their usage in a study of the association between smoking and colorectal cancer subtypes in the Nurses' Health Study and Health Professional Follow-Up Study. [ABSTRACT FROM AUTHOR]

It is increasingly common for therapies in oncology to be given in combination. In some cases, patients can benefit from the interaction between two drugs, although often at the risk of higher toxicity. A large number of designs to conduct phase I trials in this setting are available, where the objective is to select the maximum tolerated dose combination. Recently, a number of model-free (also called model-assisted) designs have provoked interest, providing several practical advantages over the more conventional approaches of rule-based or model-based designs. In this paper, we demonstrate a novel calibration procedure for model-free designs to determine their most desirable parameters. Under the calibration procedure, we compare the behaviour of model-free designs to model-based designs in a comprehensive simulation study, covering a number of clinically plausible scenarios. It is found that model-free designs are competitive with the model-based designs in terms of the proportion of correct selections of the maximum tolerated dose combination. However, there are a number of scenarios in which model-free designs offer a safer alternative. This is also illustrated in the application of the designs to a case study using data from a phase I oncology trial. [ABSTRACT FROM AUTHOR]

With the recent advances in oncology treatment, restricted mean survival time (RMST) is increasingly being used to replace the routine approach based on hazard ratios in randomized controlled trials for time-to-event outcomes. While RMST has been widely applied in single-arm and two-arm designs, challenges still exist in comparing RMST in multi-arm trials with three or more groups. In particular, it is unclear in the literature how to compare more than one intervention simultaneously or perform multiple testing based on RMST, and sample size determination is a major obstacle to its penetration to practice. In this paper, we propose a novel method of designing multi-arm clinical trials with right-censored survival endpoint based on RMST that can be applied in both phase II/III settings using a global χ 2 test as well as a modeling-based multiple comparison procedure. The framework provides a closed-form sample size formula built upon a multi-arm global test and a sample size determination procedure based on multiple-comparison in the phase II dose-finding study. The proposed method enjoys strong robustness and flexibility as it requires less a priori set-up than conventional work, and obtains a smaller sample size while achieving the target power. In the assessment of sample size, we also incorporate practical considerations, including the presence of non-proportional hazards and staggered patient entry. We evaluate the validity of our method through simulation studies under various scenarios. Finally, we demonstrate the accuracy and stability of our method by implementing it in the design of two real clinical trial examples. [ABSTRACT FROM AUTHOR]

Mediation analysis has become increasingly popular over the last decade as researchers are interested in assessing mechanistic pathways for intervention. Although available methods have increased, there are still limited options for mediation analysis with zero-inflated count variables where the distribution of response has a "cluster" of data at the zero value (i.e. distribution of number of cigarettes smoked per day, where nonsmokers cluster at zero cigarettes). The currently available methods do not obtain unbiased population average effects of mediation effects. In this paper, we propose an extension of the counterfactual approach to mediation with direct and indirect effects to scenarios where the mediator is a count variable with excess zeroes by utilizing the Marginalized Zero-Inflated Poisson Model (MZIP) for the mediator model. We derive direct and indirect effects for continuous, binary, and count outcomes, as well as adapt to allow mediator-exposure interactions. Our proposed work allows straightforward calculation of direct and indirect effects for the overall population mean values of the mediator, for scenarios in which researchers are interested in generalizing direct and indirect effects to the population. We apply this novel methodology to an application observing how alcohol consumption may explain sex differences in cholesterol and assess model performance via a simulation study comparing the proposed MZIP mediator framework to existing methods for marginal mediator effects. [ABSTRACT FROM AUTHOR]

Generalized linear mixed models are commonly used to describe relationships between correlated responses and covariates in medical research. In this paper, we propose a simple and easily implementable regularized estimation approach to select both fixed and random effects in generalized linear mixed model. Specifically, we propose to construct and optimize the objective functions using the confidence distributions of model parameters, as opposed to using the observed data likelihood functions, to perform effect selections. Two estimation methods are developed. The first one is to use the joint confidence distribution of model parameters to perform simultaneous fixed and random effect selections. The second method is to use the marginal confidence distributions of model parameters to perform the selections of fixed and random effects separately. With a proper choice of regularization parameters in the adaptive LASSO framework, we show the consistency and oracle properties of the proposed regularized estimators. Simulation studies have been conducted to assess the performance of the proposed estimators and demonstrate computational efficiency. Our method has also been applied to two longitudinal cancer studies to identify demographic and clinical factors associated with patient health outcomes after cancer therapies. [ABSTRACT FROM AUTHOR]

In clinical trials, evaluating the accuracy of risk scores (markers) derived from prognostic models for prediction of survival outcomes is of major concern. The time-dependent receiver operating characteristic curve and the corresponding area under the receiver operating characteristic curve are appealing measures to evaluate the predictive accuracy. Several estimation methods have been proposed in the context of classical right-censored data which assumes the event time of individuals are independent. In many applications, however, this may not hold true if, for example, individuals belong to clusters or experience recurrent events. Estimates may be biased if this correlated nature is not taken into account. This paper is then aimed to fill this knowledge gap to introduce a time-dependent receiver operating characteristic curve and the corresponding area under the receiver operating characteristic curve estimation method for right-censored data that take the correlated nature into account. In the proposed method, the unknown status of censored subjects is imputed using conditional survival functions given the marker and frailty of the subjects. An extensive simulation study is conducted to evaluate and demonstrate the finite sample performance of the proposed method. Finally, the proposed method is illustrated using two real-world examples of lung cancer and kidney disease. [ABSTRACT FROM AUTHOR]

In recent decades, many phase II clinical trials have used survival outcomes as the primary endpoints. If radiotherapy is involved, the competing risk issue often arises because the time to disease progression can be censored by the time to normal tissue complications, and vice versa. Besides, many existing research has examined that patients receiving the same radiotherapy dose may yield distinct responses due to their heterogeneous radiation susceptibility statuses. Therefore, the "one-size-fits-all" strategy often fails, and it is more relevant to evaluate the subgroup-specific treatment effect with the subgroup defined by the radiation susceptibility status. In this paper, we propose a Bayesian adaptive biomarker stratified phase II trial design evaluating the subgroup-specific treatment effects of radiotherapy. We use the cause-specific hazard approach to model the competing risk survival outcomes. We propose restricting the candidate radiation doses based on each patient's radiation susceptibility status. Only the clinically feasible personalized dose will be considered, which enhances the benefit for the patients in the trial. In addition, we propose a stratified Bayesian adaptive randomization scheme such that more patients will be randomized to the dose reporting more favorable survival outcomes. Numerical studies and an illustrative trial example have shown that the proposed design performed well and outperformed the conventional design ignoring the competing risk issue. [ABSTRACT FROM AUTHOR]

In recent years, with the increasing number and complexity of infectious diseases, the idea of using control charts to monitor public health and disease has been proposed. In this paper, we study multivariate control charts for monitoring a bivariate integer-valued autocorrelation process with bivariate Poisson distribution and select the optimal control scheme by comparing the performance of control charts. Furthermore, the meningococcal patient event in two states in Australia serves as an example to illustrate the application of these methods. The results show that the D exponentially weighted moving average control scheme can detect the changes in the mean value faster, which is a significant advantage. [ABSTRACT FROM AUTHOR]

The success of preclinical research hinges on exploratory and confirmatory animal studies. Traditional null hypothesis significance testing is a common approach to eliminate the chaff from a collection of drugs, so that only the most promising treatments are funneled through to clinical research phases. Balancing the number of false discoveries and false omissions is an important aspect to consider during this process. In this paper, we compare several preclinical research pipelines, either based on null hypothesis significance testing or based on Bayesian statistical decision criteria. We build on a recently published large-scale meta-analysis of reported effect sizes in preclinical animal research and elicit a non-informative prior distribution under which both approaches are compared. After correcting for publication bias and shrinkage of effect sizes in replication studies, simulations show that (i) a shift towards statistical approaches which explicitly incorporate the minimum clinically important difference reduces the false discovery rate of frequentist approaches and (ii) a shift towards Bayesian statistical decision criteria can improve the reliability of preclinical animal research by reducing the number of false-positive findings. It is shown that these benefits hold while keeping the number of experimental units low which are required for a confirmatory follow-up study. Results show that Bayesian statistical decision criteria can help in improving the reliability of preclinical animal research and should be considered more frequently in practice. [ABSTRACT FROM AUTHOR]

Traditional methods based on the assumption that the treatment distribution is a pure shift of the control distribution may not always hold. The possibility that an individual from the treatment group may not respond to the treatment motivates the use of a mixture distribution for the treatment group. This paper considers two test procedures based on the Wilcoxon rank-sum statistic for a group sequential design to detect the one-sided mixture alternative. Error spending functions are used for the allocation of error rates at each stage. The two tests are evaluated individually in determination of critical values and arm sizes and asymptotic multivariate normality is shown to hold for both. Upon comparison, the tests are presented to be asymptotically equivalent. Both test statistics maintain the Type I error rate even if F is misspecified in the design alternative. A more general definition of the treatment effect is used with the mixture distribution. Method of moments estimators and constrained k -means estimators for the treatment effect are evaluated. [ABSTRACT FROM AUTHOR]

Comparative Poisson trials of an experimental treatment versus a control typically condition on the total number of events that occur across both arms (Design A). Inference is based on the binomial distribution. Recently, an approach termed Design C to compare K experimental treatments to the same control was introduced. Under Design C without curtailment, the trial continues until a prespecified number of events occur in the control arm, leading to inference based on the negative multinomial distribution. The question remains of how advantageous it is to conduct one Design C trial comparing K experimental treatment arms to the same control arm as opposed to conducting K separate Design A trials each comparing one experimental treatment arm to a different control arm. This paper, therefore, compares the expected number of subjects to enroll for the two designs under uncurtailed and curtailed settings. The designs are evaluated when the null hypothesis and various assumptions for the alternative hypothesis hold. We simulate a variety of combinations for the Type 1 error, power, and ratio of the incidence rate of events in the experimental treatment to control arms. Design C frequently offers significant savings in terms of sample size relative to Design A. [ABSTRACT FROM AUTHOR]

The problem of misclassification in covariates is ubiquitous in survival data and often leads to biased estimates. The misclassification simulation extrapolation method is a popular method to correct this bias. However, its impact on Weibull accelerated failure time models has not been studied. In this paper, we study the bias caused by misclassification in one or more binary covariates in Weibull accelerated failure time models and explore the use of the misclassification simulation extrapolation in correcting for this bias, along with its asymptotic properties. Simulation studies are carried out to investigate the numerical properties of the resulting estimator for finite samples. The proposed method is then applied to colon cancer data obtained from the cancer registry at Memorial Sloan Kettering Cancer Center. [ABSTRACT FROM AUTHOR]

In this paper, we develop an extension of compartmental epidemiological models which is suitable for COVID-19. The model presented in this paper comprises seven compartments in the progression of the disease. This model, named as the SINTRUE (S usceptible, I nfected and pre-symptomatic, Infected and Symptomatic but N ot Tested, T ested Positive, Recorded R ecovered, U nrecorded Recovered, and E xpired) model. The proposed model incorporates transmission due to asymptomatic carriers and captures the spread of the disease due to the movement of people to/from different administrative boundaries within a country. In addition, the model allows estimating the number of undocumented infections in the population and the number of unrecorded recoveries. The associated parameters in the model can help architect the public health policy and operational management of the pandemic. The results show that the testing rate of the asymptomatic patients is a crucial parameter to fight against the pandemic. The model is also shown to have a better predictive capability than the other epidemiological models. [ABSTRACT FROM AUTHOR]

At the break of a pandemic, the protective efficacy of therapeutic interventions needs rapid evaluation. An experimental approach to the problem will not always be appropriate. An alternative route are observational studies, whether based on regional health service data or hospital records. In this paper, we discuss the use of methods of causal inference for the analysis of such data, with special reference to causal questions that may arise in a pandemic. We apply the methods by using the aid of a directed acyclic graph (DAG) representation of the problem, to encode our causal assumptions and to logically connect the scientific questions. We illustrate the usefulness of DAGs in the context of a controversy over the effects of renin aldosterone system inhibitors (RASIs) in hypertensive individuals at risk of (or affected by) severe acute respiratory syndrome coronavirus 2 disease. We consider questions concerning the existence and the directions of those effects, their underlying mechanisms, and the possible dependence of the effects on context variables. This paper describes the cognitive steps that led to a DAG representation of the problem, based on background knowledge and evidence from past studies, and the use of the DAG to analyze our hospital data and assess the interpretive limits of the results. Our study contributed to subverting early opinions about RASIs, by suggesting that these drugs may indeed protect the older hypertensive Covid-19 patients from the consequences of the disease. Mechanistic interaction methods revealed that the benefit may be greater (in a sense to be made clear) in the older stratum of the population. [ABSTRACT FROM AUTHOR]

The growth hormone-2000 biomarker method, based on the measurements of insulin-like growth factor-I and the amino-terminal pro-peptide of type III collagen, has been developed as a powerful technique for the detection of growth hormone misuse by athletes. Insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen are combined in gender-specific formulas to create the growth hormone-2000 score, which is used to determine whether growth hormone has been administered. To comply with World Anti-Doping Agency regulations, each analyte must be measured by two methods. Insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen can be measured by a number of approved methods, each leading to its own growth hormone-2000 score. Single decision limits for each growth hormone-2000 score have been introduced and developed by Bassett, Erotokritou-Mulligan, Holt, Böhning and their co-authors in a series of papers. These have been incorporated into the guidelines of the World Anti-Doping Agency. A joint decision limit was constructed based on the sample correlation between the two growth hormone-2000 scores generated from an available sample to increase the sensitivity of the biomarker method. This paper takes this idea further into a fully developed statistical approach. It constructs combined decision limits when two growth hormone-2000 scores from different assay combinations are used to decide whether an athlete has been misusing growth hormone. The combined decision limits are directly related to tolerance regions and constructed using a Bayesian approach. It is also shown to have highly satisfactory frequentist properties. The new approach meets the required false-positive rate with a pre-specified level of certainty. [ABSTRACT FROM AUTHOR]

Statistical sequential analysis of binary data is an important tool in clinical trials such as placebo-controlled trials, where a total of K individuals are randomly allocated into two groups, one of size κ 1 receiving the treatment/drug, and the other of size κ 2 for placebo. The ratio z = κ 2 / κ 1 , namely "matching ratio," determines the expected proportion of adverse events from the treatment group among the κ 1 + κ 2 individuals. Bernoulli-based designs are used for monitoring the safety of post-licensed drugs and vaccines as well. For instance, in a self-control design, z is the ratio between the risk and the control time windows. Irrespective of the type of application, the choice of z is a critical design criterion as it determines the sample size, the statistical power, the expected sample size, and the expected time to signal the sequential procedure. In this paper, we run exact calculations to offer a statistical rule of thumb for the choice of z. All the calculations and examples are performed using the R Sequential package. [ABSTRACT FROM AUTHOR]

The discriminative and predictive power of a continuous-valued marker for survival outcomes can be summarized using the receiver operating characteristic and predictiveness curves, respectively. In this paper, fully parametric and semi-parametric copula-based constructions of the joint model of the marker and the survival time are developed for characterizing, plotting, and analyzing both curves along with other underlying performance measures. The formulations require a copula function, a parametric specification for the margin of the marker, and either a parametric distribution or a non-parametric estimator for the margin of the time to event, to respectively characterize the fully parametric and semi-parametric joint models. Estimation is carried out using maximum likelihood and a two-stage procedure for the parametric and semi-parametric models, respectively. Resampling-based methods are used for computing standard errors and confidence bounds for the various parameters, curves, and associated measures. Graphical inspection of residuals from each conditional distribution is employed as a guide for choosing a copula from a set of candidates. The performance of the estimators of various classification and predictiveness measures is assessed in simulation studies, assuming different copula and censoring scenarios. The methods are illustrated with the analysis of two markers using the familiar primary biliary cirrhosis data set. [ABSTRACT FROM AUTHOR]

In medical statistics, when the effect of a binary risk factor on a binary response is of interest, relative risk is often the preferred measure due to its direct interpretation. However, statistical inference on this quantity is not as straightforward as for other measures of association, especially when further explanatory variables have to be taken into account. Starting from a review of available methods for inference on relative risk, this paper deals with small and moderate sample size settings for which we show that classical approaches can be problematic. For this reason, we propose the use of improved estimation procedures, aiming at mean or median bias reduction of the maximum likelihood estimator. In particular, these methods are developed for a new alternative specification of a model recently proposed by Richardson et al, where higher computational stability of the estimation methods is achieved. A real-data example and extensive simulation studies show that the proposed methods perform remarkably better than the standard ones. [ABSTRACT FROM AUTHOR]

Most of the studies for longitudinal quantile regression are based on the correct specification. Nevertheless, one specific model can hardly perform precisely under different conditions and assessing which conditions are (approximately) satisfied to determine the optimal one is rather difficult. In the case of the mixed effect model, the misspecification of the fixed effect part will cause a lack of predicting accuracy of random effects, and affect the efficiency of the cumulative function estimator. On the other hand, limited research has focused on incorporating multiple candidate procedures in longitudinal data analysis, which is of current emergency. This paper proposes an exponential aggregation weighting algorithm for longitudinal quantile regression. Based on the secondary smoothing loss function, we establish oracle inequalities for aggregated estimator. The proposed method is applied to evaluate the cumulative τ th quantile function for additive mixed effect model with right-censored history process, and an aggregation-based best linear prediction for random effects is constructed as well. We show that the asymptotic properties are conveniently imposed owing to the smoothing scheme. Simulation studies are carried out to exhibit the rationality, and our method is illustrated to analyze the data set from a multicenter automatic defibrillator implantation trial. [ABSTRACT FROM AUTHOR]

Factorial allow for the simultaneous evaluation of more than one treatment, by randomizing patients to their possible combinations, including control. However, the statistical power of one treatment can be influenced by the effectiveness of the other, a matter that has not been widely recognized. In this paper, we evaluate the relationship between the observed effectiveness of one treatment and the implied power for a second treatment in the same trial, under a range of conditions. We provide analytic and numerical solutions for a binary outcome, under the additive, multiplicative, and odds ratio scales for treatment interaction. We demonstrate how the minimum required sample size for a trial depends on the two treatment effects. Relevant factors include the event rate in the control group, sample size, treatment effect sizes, and Type-I error rate thresholds. We show that that power for one treatment decreases as a function of the observed effectiveness of the other treatment if there is no multiplicative interaction. A similar pattern is observed with the odds ratio scale at low control rates, but at high control rates, power may increase if the first treatment is moderately more effective than its planned value. When treatments do not interact additively, power may either increase or decrease, depending on the control event rate. We also determine where the maximum power occurs for the second treatment. We illustrate these ideas with data from two actual factorial trials. These results can benefit investigators in planning the analysis of factorial clinical trials, in particular, to alert them to the potential for losses in power when one observed treatment effect differs from its originally postulated value. Updating the power calculation and modifying the associated required sample size can then ensure sufficient power for both treatments. [ABSTRACT FROM AUTHOR]

This paper investigates statistical reproducibility of the t-test. We formulate reproducibility as a predictive inference problem and apply the nonparametric predictive inference method. Within our research framework, statistical reproducibility provides inference on the probability that the same test outcome would be reached, if the test were repeated under identical conditions. We present an nonparametric predictive inference algorithm to calculate the reproducibility of the t-test and then use simulations to explore the reproducibility both under the null and alternative hypotheses. We then apply nonparametric predictive inference reproducibility to a real-life scenario of a preclinical experiment, which involves multiple pairwise comparisons of test groups, where different groups are given a different concentration of a drug. The aim of the experiment is to decide the concentration of the drug which is most effective. In both simulations and the application scenario, we study the relationship between reproducibility and two test statistics, the Cohen's d and the p-value. We also compare the reproducibility of the t-test with the reproducibility of the Wilcoxon Mann-Whitney test. Finally, we examine reproducibility for the final decision of choosing a particular dose in the multiple pairwise comparisons scenario. This paper presents advances on the topic of test reproducibility with relevance for tests used in pharmaceutical research. [ABSTRACT FROM AUTHOR]

The generalized g-formula can be used to estimate the probability of survival under a sustained treatment strategy. When treatment strategies are deterministic, estimators derived from the so-called efficient influence function (EIF) for the g-formula will be doubly robust to model misspecification. In recent years, several practical applications have motivated estimation of the g-formula under non-deterministic treatment strategies where treatment assignment at each time point depends on the observed treatment process. In this case, EIF-based estimators may or may not be doubly robust. In this paper, we provide sufficient conditions to ensure the existence of doubly robust estimators for intervention treatment distributions that depend on the observed treatment process for point treatment interventions and give a class of intervention treatment distributions dependent on the observed treatment process that guarantee model doubly and multiply robust estimators in longitudinal settings. Motivated by an application to pre-exposure prophylaxis (PrEP) initiation studies, we propose a new treatment intervention dependent on the observed treatment process. We show there exist (1) estimators that are doubly and multiply robust to model misspecification and (2) estimators that when used with machine learning algorithms can attain fast convergence rates for our proposed intervention. Finally, we explore the finite sample performance of our estimators via simulation studies. [ABSTRACT FROM AUTHOR]

There has been an increased interest in borrowing information from historical control data to improve the statistical power for hypothesis testing, therefore reducing the required sample sizes in clinical trials. To account for the heterogeneity between the historical and current trials, power priors are often considered to discount the information borrowed from the historical data. However, it can be challenging to choose a fixed power prior parameter in the application. The modified power prior approach, which defines a random power parameter with initial prior to control the amount of historical information borrowed, may not directly account for heterogeneity between the trials. In this paper, we propose a novel approach to pick a power prior based on some direct measures of distributional differences between historical control data and current control data under normal assumptions. Simulations are conducted to investigate the performance of the proposed approach compared with current approaches (e.g. commensurate prior, meta-analytic-predictive, and modified power prior). The results show that the proposed power prior improves the study power while controlling the type I error within a tolerable limit when the distribution of the historical control data is similar to that of the current control data. The method is developed for both superiority and non-inferiority trials and is illustrated with an example from vaccine clinical trials. [ABSTRACT FROM AUTHOR]

Sample size calculations for cluster-randomised trials require inclusion of an inflation factor taking into account the intra-cluster correlation coefficient. Often, estimates of the intra-cluster correlation coefficient are taken from pilot trials, which are known to have uncertainty about their estimation. Given that the value of the intra-cluster correlation coefficient has a considerable influence on the calculated sample size for a main trial, the uncertainty in the estimate can have a large impact on the ultimate sample size and consequently, the power of a main trial. As such, it is important to account for the uncertainty in the estimate of the intra-cluster correlation coefficient. While a commonly adopted approach is to utilise the upper confidence limit in the sample size calculation, this is a largely inefficient method which can result in overpowered main trials. In this paper, we present a method of estimating the sample size for a main cluster-randomised trial with a continuous outcome, using numerical methods to account for the uncertainty in the intra-cluster correlation coefficient estimate. Despite limitations with this initial study, the findings and recommendations in this paper can help to improve sample size estimations for cluster randomised controlled trials by accounting for uncertainty in the estimate of the intra-cluster correlation coefficient. We recommend this approach be applied to all trials where there is uncertainty in the intra-cluster correlation coefficient estimate, in conjunction with additional sources of information to guide the estimation of the intra-cluster correlation coefficient. [ABSTRACT FROM AUTHOR]

Survival data with multiple outcomes are frequently encountered in biomedical investigations. An illustrative example comes from Alzheimer's Disease Neuroimaging Initiative study where the cognitively normal subjects may clinically progress to mild cognitive impairment and/or Alzheimer's disease dementia. Transition time from normal cognition to mild cognitive impairment and that from mild cognitive impairment to Alzheimer's disease are expected to be correlated within subjects and the dependence is often accommodated by the frailty (random effects). Estimation in the frailty model unavoidably involves multiple integrations which may be intractable and hence leads to severe computational challenges, especially in the presence of high-dimensional covariates. In this paper, we propose efficient minorization–maximization algorithms in the frailty model for survival data with multiple outcomes. The alternating direction method of multipliers is further incorporated for simultaneous variable selection and homogeneity pursuit via regularization and fusion. Extensive simulation studies are conducted to assess the performance of the proposed algorithms. An application to the Alzheimer's Disease Neuroimaging Initiative data is also provided to illustrate their practical utilities. [ABSTRACT FROM AUTHOR]

In sparse penalized regressions, candidate covariates of different units need to be standardized beforehand so that the coefficient sizes are directly comparable and reflect their relative impacts, which leads to fairer variable selection. However, when covariates of mixed data types (e.g. continuous, binary or categorical) exist in the same dataset, the commonly used standardization methods may lead to different selection probabilities even when the covariates have the same impact on or level of association with the outcome. In this paper, we propose a novel standardization method that targets at generating comparable selection probabilities in sparse penalized regressions for continuous, binary or categorical covariates with the same impact. We illustrate the advantages of the proposed method in simulation studies, and apply it to the National Ambulatory Medical Care Survey data to select factors related to the opioid prescription in the US. [ABSTRACT FROM AUTHOR]

In sequential testing with binary data, sample size and time to detect a signal are the key performance measures to optimize. While the former should be optimized in Phase III clinical trials, minimizing the latter is of major importance in post-market drug and vaccine safety surveillance of adverse events. The precision of the relative risk estimator on termination of the analysis is a meaningful design criterion as well. This paper presents a linear programming framework to find the optimal alpha spending that minimizes expected time to signal, or expected sample size as needed. The solution enables (a) to bound the width of the confidence interval following the end of the analysis, (b) designs with outer signaling thresholds and inner non-signaling thresholds, and (c) sequential designs with variable Bernoulli probabilities. To illustrate, we use real data on the monitoring of adverse events following the H1N1 vaccination. The numerical results are obtained using the R Sequential package. [ABSTRACT FROM AUTHOR]

When a clinical trial stops early for benefit, the maximum likelihood estimate (MLE) of the treatment effect may be subject to overestimation bias. Several authors have proposed adjusting for this bias using the conditional MLE, which is obtained by conditioning on early stopping. However, this approach has a fundamental problem in that the adjusted estimate may not be in the direction of benefit, even though the study has stopped early due to benefit. In this paper, we address this problem by embedding both the MLE and the conditional MLE within a broader class of penalised likelihood estimates, and choosing a member of the class that is a favourable compromise between the two. This penalised MLE, and its associated confidence interval, always lie in the direction of benefit when the study stops early for benefit. We study its properties using both simulations and analyses of the ENZAMET trial in metastatic prostate cancer. Conditional on stopping early for benefit, the method is found to have good unbiasedness and coverage properties, along with very favourable efficiency at earlier interim analyses. We recommend the penalised MLE as a supplementary analysis to a conventional primary analysis when a clinical trial stops early for benefit. [ABSTRACT FROM AUTHOR]

In clinical and public health studies, it is often the case that some variables relevant to the analysis are too difficult or costly to measure for all individuals in the population of interest. Rather, a subsample of these individuals must be identified for additional data collection. A sampling scheme that incorporates readily-available information for the entire target population at the design stage can increase the statistical efficiency of the intended analysis. While there is no universally optimal sampling design, under certain principles and restrictions, a well-designed and efficient sampling strategy can be implemented. In two-phase designs, efficiency can be gained by stratifying on the outcome and/or auxiliary information that is known at phase I. Additional gains in efficiency can be obtained by determining the optimal allocation of the sample sizes across the strata, which depends on the quantity that is being estimated. In this paper, the inference is concerned with one or multiple regression parameter(s) where the study units are naturally clustered and, thus, exhibit correlation in outcomes. We propose several allocation strategies within the framework of two-phase designs for the estimation of the regression parameter(s) obtained from weighted generalized estimating equations. The proposed methods extend existing theory to address the objective of the estimating regression parameters in cluster-correlated data settings by minimizing the asymptotic variance of the estimator subject to a fixed sample size. Through a comprehensive simulation study, we show that the proposed allocation schemes have the potential to yield substantial efficiency gains over alternative strategies. [ABSTRACT FROM AUTHOR]

Alzheimer's disease (AD) can be diagnosed by utilizing traditional logistic regression models to fit magnetic resonance imaging (MRI) data of brain, which is regarded as a vector of covariates. But its parameter estimation is inefficient and computationally extensive due to ultrahigh dimensionality and complicated structure of MRI data. To overcome this deficiency, this paper proposes a tensor logistic regression model (TLRM) for AD's MRI data by regarding MRI tensor as covariates. Under this framework, a tensor candecomp/parafac (CP) decomposition tool is employed to reduce ultrahigh dimensional tensor to a high dimensional level, a novel Bayesian adaptive Lasso method is developed to simultaneously select important components of tensor and estimate model parameters by incorporating the P o ´ lya-Gamma method leading a closed-form likelihood and avoiding the usage of the Metropolis-Hastings algorithm, and Gibbs sampler technique in Markov chain Monte Carlo (MCMC). A tensor's product technique is utilized to optimize the calculation program and speed up the calculation of MCMC. Bayes factor together with the path sampling approach is presented to select tensor rank in CP decomposition. Effectiveness of the proposed method is illustrated on simulation studies and an MRI data analysis. [ABSTRACT FROM AUTHOR]

Cure models are a class of time-to-event models where a proportion of individuals will never experience the event of interest. The lifetimes of these so-called cured individuals are always censored. It is usually assumed that one never knows which censored observation is cured and which is uncured, so the cure status is unknown for censored times. In this paper, we develop a method to estimate the probability of cure in the mixture cure model when some censored individuals are known to be cured. A cure probability estimator that incorporates the cure status information is introduced. This estimator is shown to be strongly consistent and asymptotically normally distributed. Two alternative estimators are also presented. The first one considers a competing risks approach with two types of competing events, the event of interest and the cure. The second alternative estimator is based on the fact that the probability of cure can be written as the conditional mean of the cure status. Hence, nonparametric regression methods can be applied to estimate this conditional mean. However, the cure status remains unknown for some censored individuals. Consequently, the application of regression methods in this context requires handling missing data in the response variable (cure status). Simulations are performed to evaluate the finite sample performance of the estimators, and we apply them to the analysis of two datasets related to survival of breast cancer patients and length of hospital stay of COVID-19 patients requiring intensive care. [ABSTRACT FROM AUTHOR]

Human microbiome research has become a hot-spot in health and medical research in the past decade due to the rapid development of modern high-throughput. Typical data in a microbiome study consisting of the operational taxonomic unit counts may have over-dispersion and/or structural zero issues. In such cases, negative binomial models can be applied to address the over-dispersion issue, while zero-inflated negative binomial models can be applied to address both issues. In practice, it is essential to know if there is zero-inflation in the data before applying negative binomial or zero-inflated negative binomial models because zero-inflated negative binomial models may be unnecessarily complex and difficult to interpret, or may even suffer from convergence issues if there is no zero-inflation in the data. On the other hand, negative binomial models may yield invalid inferences if the data does exhibit excessive zeros. In this paper, we develop a new test for detecting zero-inflation resulting from a latent class of subjects with structural zeros in a negative binomial regression model by directly comparing the amount of observed zeros with what would be expected under the negative binomial regression model. A closed form of the test statistic as well as its asymptotic properties are derived based on estimating equations. Intensive simulation studies are conducted to investigate the performance of the new test and compare it with the classical Wald, likelihood ratio, and score tests. The tests are also applied to human gut microbiome data to test latent class in microbial genera. [ABSTRACT FROM AUTHOR]

Recently, various methods have been developed to estimate the sample mean and standard deviation when only the sample size, and other selected sample summaries are reported. In this paper, we provide a unified approach to optimal estimation that can be easily adopted when only some summary statistics are reported. We show that the proposed estimators have the lowest variance among linear unbiased estimators. We also show that in the most commonly reported cases, that is, when only a three-number or five-number summary is reported, the newly proposed estimators match the previously developed estimators. Finally, we demonstrate the performance of the estimators numerically. [ABSTRACT FROM AUTHOR]

Evidence from observational studies has become increasingly important for supporting healthcare policy making via cost-effectiveness analyses. Similar as in comparative effectiveness studies, health economic evaluations that consider subject-level heterogeneity produce individualized treatment rules that are often more cost-effective than one-size-fits-all treatment. Thus, it is of great interest to develop statistical tools for learning such a cost-effective individualized treatment rule under the causal inference framework that allows proper handling of potential confounding and can be applied to both trials and observational studies. In this paper, we use the concept of net-monetary-benefit to assess the trade-off between health benefits and related costs. We estimate cost-effective individualized treatment rule as a function of patients' characteristics that, when implemented, optimizes the allocation of limited healthcare resources by maximizing health gains while minimizing treatment-related costs. We employ the conditional random forest approach and identify the optimal cost-effective individualized treatment rule using net-monetary-benefit-based classification algorithms, where two partitioned estimators are proposed for the subject-specific weights to effectively incorporate information from censored individuals. We conduct simulation studies to evaluate the performance of our proposals. We apply our top-performing algorithm to the NIH-funded Systolic Blood Pressure Intervention Trial to illustrate the cost-effectiveness gains of assigning customized intensive blood pressure therapy. [ABSTRACT FROM AUTHOR]

This paper introduces the event-probability function, a measure of occurrence of an event of interest over time, defined as the instantaneous probability of an event at a given time point conditional on having survived until that point. Unlike the hazard function, the event-probability function is a proper probability. This paper describes properties and interpretation of the event-probability function, presents its connection with other popular functions, such as the hazard and survival functions, proposes practical flexible proportional-odds models for estimating conditional event-probabilities given covariates with possibly censored and truncated observations, discusses the theoretical and computational aspects of parameter estimation, and applies the proposed models for assessing mortality in patients with metastatic renal carcinoma from a randomized clinical trial. [ABSTRACT FROM AUTHOR]

This functional joint model paper is motivated by a chronic kidney disease study post kidney transplantation. The available kidney organ is a scarce resource because millions of end-stage renal patients are on the waiting list for kidney transplantation. The life of the transplanted kidney can be extended if the progression of the chronic kidney disease stage can be slowed, and so a major research question is how to extend the transplanted kidney life to maximize the usage of the scarce organ resource. The glomerular filtration rate is the best test to monitor the progression of the kidney function, and it is a continuous longitudinal outcome with repeated measures. The patient's survival status is characterized by time-to-event outcomes including kidney transplant failure, death with kidney function, and death without kidney function. Few studies have been carried out to simultaneously investigate these multiple clinical outcomes in chronic kidney disease stage patients based on a joint model. Therefore, this paper proposes a new functional joint model from this clinical chronic kidney disease study. The proposed joint models include a longitudinal sub-model with a flexible basis function for subject-level trajectories and a competing-risks sub-model for multiple time-to event outcomes. The different association structures can be accomplished through a time-dependent function of shared random effects from the longitudinal process or the whole longitudinal history in the competing-risks sub-model. The proposed joint model that utilizes basis function and competing-risks sub-model is an extension of the standard linear joint models. The application results from the proposed joint model can supply some useful clinical references for chronic kidney disease study post kidney transplantation. [ABSTRACT FROM AUTHOR]

Joint modelling of longitudinal measurements and time to event, with longitudinal and event submodels coupled by latent state variables, has wide application in biostatistics. Standard methods for fitting these models require numerical integration to marginalize over the trajectories of the latent states, which is computationally prohibitive for high-dimensional data and for the large data sets that are generated from electronic health records. This paper describes an alternative model-fitting approach based on sequential Bayesian updating, which allows the likelihood to be factorized as the product of the likelihoods of a state-space model and a Poisson regression model. Updates for linear Gaussian state-space models can be efficiently generated with a Kalman filter and the approach can be implemented with existing software. An application to a publicly available data set is demonstrated. [ABSTRACT FROM AUTHOR]

The serial interval of an infectious disease, commonly interpreted as the time between the onset of symptoms in sequentially infected individuals within a chain of transmission, is a key epidemiological quantity involved in estimating the reproduction number. The serial interval is closely related to other key quantities, including the incubation period, the generation interval (the time between sequential infections), and time delays between infection and the observations associated with monitoring an outbreak such as confirmed cases, hospital admissions, and deaths. Estimates of these quantities are often based on small data sets from early contact tracing and are subject to considerable uncertainty, which is especially true for early coronavirus disease 2019 data. In this paper, we estimate these key quantities in the context of coronavirus disease 2019 for the UK, including a meta-analysis of early estimates of the serial interval. We estimate distributions for the serial interval with a mean of 5.9 (95% CI 5.2; 6.7) and SD 4.1 (95% CI 3.8; 4.7) days (empirical distribution), the generation interval with a mean of 4.9 (95% CI 4.2; 5.5) and SD 2.0 (95% CI 0.5; 3.2) days (fitted gamma distribution), and the incubation period with a mean 5.2 (95% CI 4.9; 5.5) and SD 5.5 (95% CI 5.1; 5.9) days (fitted log-normal distribution). We quantify the impact of the uncertainty surrounding the serial interval, generation interval, incubation period, and time delays, on the subsequent estimation of the reproduction number, when pragmatic and more formal approaches are taken. These estimates place empirical bounds on the estimates of most relevant model parameters and are expected to contribute to modeling coronavirus disease 2019 transmission. [ABSTRACT FROM AUTHOR]

In the recent COVID-19 pandemic, a wide range of epidemiological modelling approaches were used to predict the effective reproduction number, R(t), and other COVID-19-related measures such as the daily rate of exponential growth, r(t). These candidate models use different modelling approaches or differing assumptions about spatial or age-mixing, and some capture genuine uncertainty in scientific understanding of disease dynamics. Combining estimates using appropriate statistical methodology from multiple candidate models is important to better understand the variation of these outcome measures to help inform decision-making. In this paper, we combine estimates for specific UK nations/regions using random-effects meta-analyses techniques, utilising the restricted maximum-likelihood (REML) method to estimate the heterogeneity variance parameter, and two approaches to calculate the confidence interval for the combined estimate: the standard Wald-type and the Knapp and Hartung (KNHA) method. As estimates in this setting are derived using model predictions, each with varying degrees of uncertainty, equal-weighting is favoured over the standard inverse-variance weighting to avoid potential up-weighting of models providing estimates with lower levels of uncertainty that are not fully accounting for inherent uncertainties. Both equally-weighted models using REML alone and REML+KNHA approaches were found to provide similar variation for R(t) and r(t), with both approaches providing wider, and therefore more conservative, confidence intervals around the combined estimate compared to the standard inverse-variance weighting approach. Utilising these meta-analysis techniques has allowed for statistically robust combined estimates to be calculated for key COVID-19 outcome measures. This in turn allows timely and informed decision-making based on all available information. [ABSTRACT FROM AUTHOR]

Excess mortality is an important measure of the scale of the coronavirus-2019 pandemic. It includes both deaths caused directly by the pandemic, and deaths caused by the unintended consequences of containment such as delays to accessing care or postponements of healthcare provision in the population. In 2020 and 2021, in England, multiple groups have produced measures of excess mortality during the pandemic. This paper describes the data and methods used in five different approaches to estimating excess mortality and compares their estimates. The fundamental principles of estimating excess mortality are described, as well as the key commonalities and differences between five approaches. Two of these are based on the date of registration: a quasi-Poisson model with offset and a 5-year average; and three are based on date of occurrence: a Poisson model without offset, the European monitoring of excess mortality model and a synthetic controls model. Comparisons between estimates of excess mortality are made for the period March 2020 through March 2021 and for the two waves of the pandemic that occur within that time-period. Model estimates are strikingly similar during the first wave of the pandemic though larger differences are observed during the second wave. Models that adjusted for reduced circulation of winter infection produced higher estimates of excess compared with those that did not. Models that do not adjust for reduced circulation of winter infection captured the effect of reduced winter illness as a result of mobility restrictions during the period. None of the estimates captured mortality displacement and therefore may underestimate excess at the current time, though the extent to which this has occurred is not yet identified. Models use different approaches to address variation in data availability and stakeholder requirements of the measure. Variation between estimates reflects differences in the date of interest, population denominators and parameters in the model relating to seasonality and trend. [ABSTRACT FROM AUTHOR]

Spatial data from high-resolution images abound in many scientific disciplines. For example, single-molecule localization microscopy, such as stochastic optical reconstruction microscopy, provides super-resolution images to help scientists investigate co-localization of proteins and hence their interactions inside cells, which are key events in living cells. However, there are few accurate methods for analyzing co-localization in super-resolution images. The current methods and software are prone to produce false-positive errors and are restricted to only 2-dimensional images. In this paper, we develop a novel statistical method to effectively address the problems of unbiased and robust quantification and comparison of protein co-localization for multiple 2- and 3-dimensional image datasets. This method significantly improves the analysis of protein co-localization using super-resolution image data, as shown by its excellent performance in simulation studies and an analysis of co-localization of protein light chain 3 and lysosomal-associated membrane protein 1 in cell autophagy. Moreover, this method is directly applicable to co-localization analyses in other disciplines, such as diagnostic imaging, epidemiology, environmental science, and ecology. [ABSTRACT FROM AUTHOR]